“Convergence science has advanced across many fronts, from nanotechnology to regenerative tissue,” says Nobel Laureate Phil Sharp of MIT. “But the funding allocated for convergence research in biomedical science is small and needs to be expanded. In fact, there is no federal agency with the responsibility to fund convergence in biomedical research.”
UK/US Life science consulting firm Alacrita launches benefit auction for lunch with pharma exec to benefit Water Aid in developing world.
AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech,of the Roche Group, for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. The agreement is valued at $400M.
New Cambridge Observer’s Anita Harris on BIO-IT World 2012, describing the promise and problems presented by burgeoning of health care data.
On my way to a meeting at MIT, I happened to spot some stunning photos through the window of what turned out to be the Philip Alden Russell Gallery David H. Koch Institute for Integrative Cancer Research. While cancer research would not seem to be much of a draw, the gallery is well worth a visit.